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Crystal Structure and Activity Studies of the C11 Cysteine Peptidase from 
Parabacteroides merdae in the Human Gut Microbiome.  
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ABSTRACT 
Clan CD cysteine peptidases, a structurally 
related group of peptidases that include 
mammalian caspases, exhibit a wide range of 
important functions, along with a variety of 
specificities and activation mechanisms. 
However, for the clostripain family (denoted 
C11), little is currently known. Here, we 
describe the first crystal structure of a C11 
protein from the human gut bacterium, 
Parabacteroides merdae (PmC11), determined 
to 1.7 Å resolution. PmC11 is a monomeric 
cysteine peptidase that comprises an extended 
caspase-like D/E/D sandwich and an unusual C-
terminal domain. It shares core structural 
elements with clan CD cysteine peptidases but 
otherwise structurally differs from the other 
families in the clan. These studies also revealed 
a well-ordered break in the polypeptide chain at 
K147, resulting in a large conformational 
rearrangement close to the active site. 
Biochemical and kinetic analysis revealed K147 
to be an intramolecular processing site at which 
cleavage is required for full activation of the 
enzyme, suggesting an auto-inhibitory 
mechanism for self-preservation. PmC11 has an 
acidic binding pocket and a preference for basic 
substrates, and accepts both Arg and Lys 
substrates and does not require Ca2+ for activity. 
Collectively, these data provide insights into the 
mechanism and activity of PmC11 and a detailed 
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framework for studies on C11 peptidases from other phylogenetic kingdoms.  
 
INTRODUCTION
 
Cysteine peptidases play crucial roles in the 
virulence of bacterial and other eukaryotic 
pathogens. In the MEROPS peptidase database 
(1), clan CD contains groups (or families) of 
cysteine peptidases that share some highly 
conserved structural elements (2). Clan CD 
families are typically described using the name 
of their archetypal, or founding, member and 
also given an identification number preceded by 
a ‘C’, to denote cysteine peptidase. Whilst seven 
families (C14 is additionally split into three 
subfamilies) have been described for this clan, 
crystal structures have only been determined 
from four: legumain (C13)(3), caspase 
(C14a)(4), paracaspase (C14b(P)(5), 
metacaspase (C14b(M)(6), gingipain (C25)(7) 
and the cysteine peptidase domain (CPD) of 
various toxins (C80)(8). No structural 
information is available for clostripain (C11), 
separase (C50) or PrtH–peptidase (C85).  
 
Clan CD enzymes have a highly conserved 
His/Cys catalytic dyad and exhibit strict 
specificity for the P1 residue of their substrates. 
However, despite these similarities, clan CD 
forms a functionally diverse group of enzymes: 
the overall structural diversity between (and at 
times within) the various families provides these 
peptidases with a wide variety of substrate 
specificities and activation mechanisms. Several 
members are initially expressed as proenzymes, 
demonstrating self-inhibition prior to full 
activation (2). 
 
The archetypal and arguably most notable 
family in the clan is that of the mammalian 
caspases (C14a), although clan CD members are 
distributed throughout the entire phylogenetic 
kingdom and are often required in fundamental 
biological processes (2). Interestingly, little is 
known about the structure or function of the C11 
proteins, despite their wide spread distribution 
(1) and its archetypal member, clostripain from 
Clostridium histolyticum, being first reported in 
the literature in 1938 (9). Clostripain has been 
described as an arginine-specific peptidase with 
a requirement for Ca2+ (10) and loss of an 
internal nonapeptide for full activation; lack of 
structural information on the family appears to 
have prohibited further investigation.  
 
As part of an ongoing project to characterize 
commensal bacteria in the microbiome that 
inhabit the human gut, the structure of C11 
peptidase, PmC11, from Parabacteroides 
merdae was determined using the JCSG HTP 
structural biology pipeline (11) and now has 
been analysed to provide the first 
structure/function correlation for a C11 
peptidase.  
 
EXPERIMENTAL PROCEDURES 
 
 Cloning, expression, purification, 
crystallization, and structure determination of 
PmC11 were carried out using standard JCSG 
(http://www.jcsg.org) protocols (11) as follows.  
 
Cloning - Clones were generated using the 
Polymerase Incomplete Primer Extension (PIPE) 
cloning method (12) The gene encoding PmC11 
(SP5111E) was amplified by polymerase chain 
reaction (PCR) from Parabacteroides merdae 
genomic DNA using PfuTurbo DNA polymerase 
(Stratagene), using I-PIPE primers that included 
sequences for the predicted 5' and 3' ends (shown 
below). The expression vector, pSpeedET, which 
encodes an amino-terminal tobacco etch virus 
(TEV) protease-cleavable expression and 
purification tag 
(MGSDKIHHHHHHENLYFQ/G), was PCR 
amplified with V-PIPE (Vector) primers. V-PIPE 
and I-PIPE PCR products were mixed to anneal 
the amplified DNA fragments together. 
Escherichia coli GeneHogs (Invitrogen) 
competent cells were transformed with the I-PIPE 
/ V-PIPE mixture and dispensed on selective LB-
agar plates. The cloning junctions were confirmed 
by DNA sequencing. The plasmid encoding the 
full-length protein was deposited in the 
PSI:Biology Materials Repository at the DNASU 
plasmid repository (PmCD00547516). For 
structure determination, using the PIPE method 
for soluble protein expression, the gene segment 
encoding residues M1-N22 was deleted since 
these residues were predicted to correspond to a 
signal peptide using SignalP (13). 
 
Protein Expression and Selenomethionine–
incorporation (SeMet) – The expression 
plasmid for the truncated PmC11construct was 
transformed into E. coli GeneHogs competent 
cells and grown in minimal media 
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supplemented with SeMet and  ȝJ P/-1 
kanamycin at 37 qC using a GNF fermentor 
(14). A methionine auxotrophic strain was not 
required as SeMet is incorporated via the 
inhibition of methionine biosynthesis (15,16). 
Protein expression was induced using 0.1% 
(w/v) L-arabinose and the cells left to grow for 
a further 3 h at 37 qC. At the end of the cell 
culture, lysozyme was added to all samples to a 
final concentration of 250 ȝJP/-1 and the cells 
harvested and stored at -20 qC, until required. 
Primers used in this section are as follows:  
I-PIPE(forward): 
CTGTACTTCCAGGGCGAGACTCCGGAAC
CCCGGACAACCCGC,  
I-PIPE (reverse): 
AATTAAGTCGCGTTATTCATAAACTGCC
TTATACCAGCCGAC,  
V-PIPE (forward): 
TAACGCGACTTAATTAACTCGTTTAAAC
GGTCTCCAGC,  
V-PIPE (reverse): 
GCCCTGGAAGTACAGGTTTTCGTGATGA
TGATGATGAT. 
 
Protein purification for crystallisation. Cells 
were resuspended, homogenized and lysed by 
sonication in 40 mM Tris (pH 8.0), 300 mM 
NaCl, 10 mM imidazole and 1 mM Tris (2-
carboxyethyl) phosphine hydrochloride (TCEP) 
(Lysis Buffer 1) containing 0.4 mM MgSO4 and 
1 PL of 250 U PL-1 Benzonase (Sigma). The 
cell lysate was then clarified by centrifugation 
(32,500 g for 25 min at 4 qC) before being 
passed over Ni2+–chelating resin equilibrated in 
Lysis Buffer 1 and washed in the same buffer 
supplemented with 40 mM imidazole and 10% 
(v/v) glycerol. The protein was subsequently 
eluted in 20 mM Tris (pH 8.0), 150 mM NaCl, 
10% (v/v) glycerol, 1 mM TCEP and 300 mM 
imidazole and the fractions containing the 
protein pooled.  
 To remove the His-tag, PmC11 was 
exchanged into 20 mM Tris (pH 8.0), 150 mM 
NaCl, 30 mM imidazole and 1 mM TCEP using 
a PD-10 column (GE Healthcare), followed by 
incubation with 1 mg of His-tagged TEV 
protease per 15 mg of protein for 2 h at room 
temperature and subsequent overnight 
incubation at 4qC. The sample was centrifuged 
to remove any precipitated material (13,000 g 
for 10 min at 4qC) and the supernatant loaded 
onto Ni2+–chelating resin equilibrated with 20 
mM Tris (pH 8.0), 150 mM NaCl, 30 mM 
imidazole and 1 mM TCEP and washed with 
the same buffer. The flow-through and wash 
fractions were collected and concentrated to 
13.3 mg mL-1 using Amicon Ultra-15 5K 
centrifugal concentrators (Millipore). 
 
Crystallisation and Data Collection. PmC11 was 
crystallized using the nanodroplet vapour 
diffusion method using standard JCSG 
crystallization protocols (11). Drops were 
comprised of 200 nl protein solution mixed with 
200 nl crystallization solution in 96-well sitting-
GURSSODWHVHTXLOLEUDWHGDJDLQVWDȝOUHVHUYRLU
Crystals of PmC11 were grown at 4qC in  
mother liquor consisting of 0.2 M NHΏH΍POΏ, 
20% PEG-3350 (JCSG Core Suite I). Crystals 
were flash cooled in liquid nitrogen using 10% 
ethylene glycol as a cryoprotectant prior to data 
collection and initial screening for diffraction 
was carried out using the Stanford Automated 
Mounting system (SAM) (17) at the Stanford 
Synchrotron Radiation Lightsource (SSRL, 
Menlo Park, CA). Single wavelength anomalous 
dispersion (SAD) diffraction data were collected 
using a wavelength of 0.9793 Å, at the 
Advanced Light Source (ALS, beamline 8.2.2, 
Berkeley, CA) on an ADSC Quantum 315 CCD 
detector. The data were indexed and integrated 
with XDS (18) and scaled using XSCALE (18). 
The diffraction data were indexed in space group 
P21 with a = 39.11, b = 108.68, c = 77.97 Å and 
E = 94.32°. The unit cell contained two 
molecules in the asymmetric unit (ASU) 
resulting in a solvent content of 39% (Matthews’ 
coefficient (Vm) of 2.4 Å3 Da-1).  
 
Structure Determination—The PmC11 
structure was determined by the SAD method 
using an X-ray wavelength corresponding to the 
peak of the selenium K edge. Initial phases were 
derived using the autoSHARP interface (19), 
which included density modification with 
SOLOMON (20). Good quality electron density 
was obtained at 1.7 Å resolution, allowing an 
initial model to be obtained by automated model 
building with ARP/wARP (21). Model 
completion and refinement were iteratively 
performed with COOT (22) and REFMAC 
(23,24) to produce a final model with an Rcryst 
and Rfree of 14.3% and 17.5%, respectively. The 
refinement included experimental phase 
restraints in the form of Hendrickson-Lattman 
coefficients, TLS refinement with one TLS 
group per molecule in the ASU, and NCS 
restraints. The refined structure contains residues 
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24–375 and 28–375 for the two molecules in the 
crystallographic ASU. Structural validation was 
carried using the JCSG Quality Control Server 
(http://smb.slac.stanford.edu/jcsg/QC/) that 
analyses both the coordinates and data using a 
variety of structural validation tools to confirm 
the stereochemical quality of the model (ADIT 
(25), MOLPROBITY (26), and WHATIF 5.0 
(27) and agreement between model and data 
(SGCHECK (28) and RESOLVE (29). All of the 
main-chain torsion angles were in the allowed 
regions of the Ramachandran plot and the 
MolProbity overall clash score for the structure 
was 2.09 (within the 99th percentile for its 
resolution). The atomic coordinates and structure 
factors for PmC11 have been deposited in the 
Protein Data Bank (PDB, www.wwpdb.org) 
with the accession code 3UWS. Data collection, 
model and refinement statistics are reported in 
Table 1. 
 
Structural Analysis—The primary sequence 
alignment with assigned secondary structure was 
prepared using CLUSTAL OMEGA (30) and 
ALINE (31). The topology diagram was 
produced with TOPDRAW (32) and all 3D 
structural figures were prepared with PyMol (33) 
with the electrostatic surface potential 
additionally calculated with APBS (18) 
contoured at ±5 kT/e. Architectural comparisons 
with known structures revealed that PmC11 was 
most structurally similar to caspase-7, gingipain-
K and legumain (PBD IDs 4hq0, 4tkx, and 
4awb, respectively). The statistical significance 
of the structural alignment between PmC11 and 
both caspase-7 and gingipain-K was reported to 
be equivalent (Z-score of 9.2) with legumain 
giving a very similar result (Z-score of 9.1). Of 
note, the E-strand topology of the CDP domains 
of Clostridium difficile toxin B (family C80; 
TcdB; PDB ID 3pee) is identical to that 
observed in the PmC11 E-sheet but the Z-score 
from DaliLite was notably less at 7.6. It is 
possible that the PmC11 structure is more 
closely related to the C80 family than other 
families in clan CD, and appear to reside on the 
same branch of the phylogenetic tree based on 
structure (2). 
 
Protein production for biochemical assays—The 
PmCD00547516 plasmid described above was 
obtained from the PSI:Biology Materials 
Repository and used to generate a cleavage site 
mutant PmC11K147A and an active-site mutant 
PmC11C179A using the QuikChange Site-directed 
Mutagenesis kit (Stratagene) as per the 
manufacturer’s instructions using the following 
primers:   
K147A mutant (forward): 
CAGAATAAGCTGGCAGCGTTCGGACAGG
ACG,  
K147A mutant (reverse): 
CGTCCTGTCCGAACGCTGCCAGCTTATTC
TG:  
C179A mutant (forward): 
CCTGTTCGATGCCGCCTACATGGCAAGC: 
C179A mutant (reverse): 
GCTTGCCATGTAGGCGGCATCGAACAGG. 
The expression plasmids containing PmC11 were 
transformed into E. coli BL21 Star (DE3) and 
grown in Luria-Bertani media containing ȝJ
mL-1 kanamycin at 37 qC until an optical density 
(600 nm) of ~0.6 was reached. L-arabinose was 
added to a final concentration of 0.2% (w/v) and 
the cells incubated overnight at 25 qC.  
Compared to the protein production for 
crystallography, a slightly modified purification 
protocol was employed. Initially, the cells were 
resuspended in 20 mM sodium phosphate (pH 
7.5), 150 mM NaCl (Lysis Buffer 2) containing 
an EDTA-free protease inhibitor cocktail 
(cOmplete, Roche). Cells were disrupted by three 
passages (15 KPSI) through a One-Shot cell 
disruptor (Constant Systems) followed by 
centrifugation at 20,000 g for 20 min at 4°C. The 
supernatant was collected and sterile-filtered (0.2 
Pm) before being applied to a 5 mL HisTrap HP 
column (GE Healthcare) equilibrated in Lysis 
Buffer 2 containing 25 mM imidazole, and the 
protein was eluted in the same buffer containing 
250 mM imidazole. The peak fractions were 
pooled and buffer exchanged into the assay 
buffer (20 mM Tris, 150 mM NaCl, pH 8.0) 
using a PD-10 column. When required, purified 
PmC11 was concentrated using Vivaspin 2 30 K 
centrifugal concentrators (Sartorius). Protein 
concentration was routinely measured using 
Bradford’s reagent (BioRad) with a BSA 
standard. 
 
Fluorogenic substrate activity assays—The 
release of the fluorescent group AMC (7-Amino 
4-Methyl Coumarin) from potential peptide 
substrates was used to assess the activity of 
PmC11. Peptidase activity was tested using 20 
µg PmC11 and 100 PM substrate (unless 
otherwise stated) in assay buffer to a final 
reaction volume of 200 µL and all samples were 
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incubated (without substrate) at 37 °C for 16 h 
prior to carrying out the assay. The substrate and 
plate reader were brought to 37 °C for 20 min 
prior to the addition of the PmC11 and samples 
prepared without PmC11 were used as blanks 
(negative controls). The curves were plotted 
using the blank-corrected fluorescence units 
against the time of acquisition (in min). The 
assays were carried out in black 96-well flat-
bottomed plates (Greiner).  AMC fluorescence 
was measured using a PHERAstar FS plate 
reader (BMG Labtech) with excitation and 
emission wavelengths of 355 nm and of 460 nm, 
respectively.  
To investigate the substrate specificity of 
PmC11, substrates Z-GGR-AMC, Bz-R-AMC, 
Z-GP-AMC, Z-HGP-AMC, Ac-DEVD-AMC (all 
Bachem), BOC-VLK-AMC and BOC-K-AMC 
(both PeptaNova) were prepared at 100 mM in 
100% DMSO. The amount of AMC (µmoles) 
released was calculated by generating an AMC 
standard curve (as described (34)) and the 
specific activity of PmC11 was calculated as 
pmoles of AMC released per min per mg of the 
protein preparation. 
The reaction rates (Vmax) and Km values were 
determined for mutants PmC11K147A and 
PmC11C179A by carrying out the activity assay at 
varying concentrations of Bz-R-AMC between 0 
and 600 µM. The blank-corrected relative 
fluorescence units were plotted against time 
PLQ ZLWK ǻ)87 JLYLQJ WKH UHDFWLRQ UDWH 7KH
Km and Vmax of PmC11 and PmC11K147A 
against an R-AMC substrate were determined 
from the Lineweaver-Burk plot as described (34), 
calculated using GraphPad Prism6 software. All 
experiments were carried out in triplicate ± SD.  
 
Effect of VRPR-FMK on PmC11— To test the 
effect of the inhibitor on the activity of PmC11, 
25 µM of Z-VRPR-FMK (100mM stock in 100% 
DMSO, Enzo Life Sciences), 20 µg PmC11, 100 
µM R-AMC substrate, 1 mM EGTA were 
prepared in the assay buffer and the activity assay 
carried out as described above. A gel-shift assay, 
to observe Z-VRPR-FMK binding to PmC11, 
was also set up using 20 µg PmC11, 25 µM 
inhibitor, 1 mM EGTA in assay buffer. The 
reactions were incubated at 37 °C for 20 min 
before being stopped by the addition SDS/PAGE 
sample buffer. Samples were analysed by loading 
the reaction mixture on a 10% NuPAGE Bis-Tris 
gel using MES buffer. 
Effect of cations on PmC11—The enzyme 
activity of PmC11 was tested in presence of 
various divalent cations: Mg2+, Ca2+, Mn2+, Co2+, 
Fe2+, Zn2+ and Cu2+. The final concentration of 
the salts (MgSO4, CaCl2, MnCl2, CoCl2, FeSO4, 
ZnCl2, and CuSO4) was 1 mM and a control was 
set up without divalent ions but with addition of 
1 mM EGTA as the control. The assay was set up 
using 20 mg PmC11, 1 mM salts, 100 µM R-
AMC substrate, and the assay buffer, and 
incubated at 37°C for 16 h. The activity assay 
was carried out as described above. 
Size exclusion chromatography— Affinity-
purified PmC11 was loaded onto a HiLoad 16/60 
Superdex 200 gel filtration column (GE 
Healthcare) equilibrated in the assay buffer. The 
apparent molecular weight of PmC11 was 
determined from calibration curves based on 
protein standards of known molecular weights. 
Auto-processing profile of PmC11—Auto-
processing of PmC11 was evaluated by 
incubating the enzyme at 37°C and removing 
samples at one hour intervals for from 0 to 16 
hours and placing into SDS/PAGE loading 
buffer to stop the processing. Samples were then 
analysed on a 4-12% NuPAGE (Thermo 
Fischer) Novex Bis-Tris gel run in MES buffer. 
Auto-processing cleavage site analysis— To 
investigate whether processing is a result of intra 
or inter-molecular cleavage the PmC11C179A 
mutant was incubated with increasing 
concentrations of activated PmC11 (0, 0.1, 0.2, 
0.5, 1, 2 and 5 µg). The final assay volume was 
40 µL and the proteins were incubated at 37°C 
for 16 h in the PmC11 assay buffer. To stop the 
reaction, NuPAGE sample buffer was added to 
the protein samples and 20 µL was analysed on 
10% NuPAGE Novex Bis-Tris gel using MES 
buffer. These studies revealed no apparent 
cleavage of PmC11C179A by the active enzyme at 
low concentrations of PmC11 and that only 
limited cleavage was observed when the ratio of 
active enzyme (PmC11: PmC11C179A) was 
increased to ~1:10 and 1:4. 
 
RESULTS  
 
Structure of PmC11—The crystal structure of 
the catalytically active form of PmC11 revealed 
an extended caspase-like D/E/D sandwich 
architecture comprised of a central nine-stranded 
E-sheet, with an unusual C-terminal domain 
(CTD), starting at residue K250. A single 
cleavage was observed in the polypeptide chain 
at K147 (Figs 1A, B), where both ends of the 
cleavage site are fully visible and well-ordered 
in the electron density. The central nine-stranded 
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E-sheet (E1–E9) of PmC11 consists of six 
parallel and three anti-parallel E-strands with 
4Ĺ3Ļ2Ĺ1Ĺ5Ĺ6Ĺ7Ļ8Ļ9Ĺ topology (Fig. 1A) and the 
overall structure includes 14 D-helices with six 
of these (D1–D2 and D4–D7) closely surrounding 
the E-sheet in an approximately parallel 
orientation. Helices D1, D7and D6 are located on 
one side of the E-sheet with D2, D4 and D5 on 
the opposite side (Fig 1A). Helix D3 sits at the 
end of the loop following E5 (L5), just preceding 
the K147 cleavage site, with both L5 and D3 
pointing away from the central E-sheet and 
towards the CTD, which starts with D8. The 
structure also includes two short E-hairpins (EA–
EB and ED–EE) and a small E-sheet (EC–EF), 
which is formed from two distinct regions of the 
sequence (EC precedes D11 Į DQG ȕ while 
EF follows WKHȕ'-EE hairpin) in the middle of 
the CTD (Fig. 1B). 
The CTD of PmC11 is composed of a tight 
helical bundle formed from helices D8–D14 and 
includes strands EC and EF, and E-hairpin ED–
EE. The CTD sits entirely on one side of the 
enzyme interacting only with D3, D5, E9 and the 
loops surrounding E8. Of the interacting 
secondary structure elements (SSEs), D5 is 
perhaps the most interesting. This helix makes a 
total of eight hydrogen bonds with the CTD, 
including one salt bridge (R191–D255) and is 
surrounded by the CTD on one side and the main 
core of the enzyme on the other, acting like a 
linchpin holding both components together (Fig. 
1C). 
 Structural comparisons—PmC11 is, as 
expected, most structurally similar to other 
members of clan CD with the top hits in a search 
of known structures being caspase-7, gingipain-
K and legumain (PBD IDs 4hq0, 4tkx, and 
4awb, respectively) (Table 2). The C-terminal 
domain is unique to PmC11 within clan CD and 
structure comparisons for this domain alone does 
not produce any hits in the PDB (DaliLite, 
PDBeFold), suggesting a completely novel fold. 
As the archetypal and arguably most well 
studied member of clan CD, the caspases were 
used as the basis to investigate the 
structure/function relationships in PmC11, with 
caspase-7 as the representative member. Six of 
the central E-strands in PmC11 (ȕ–ȕDQGȕ–
ȕVKDUH WKHVDPHWRSRORJ\DV WKH six-stranded 
E-sheet found in caspases, with strands E3, E4 
and E9 located on the outside of this core 
structure (2) (Fig. 1B, box). H133 and C179 
were found at locations structurally homologous 
to the caspase catalytic dyad, and other clan CD 
structures (2), at the C-termini of strands ȕ5 and 
ȕ UHVSHFWLYHO\ )LJV $ % DQG 2A). 
Additionally, a multiple sequence alignment of 
C11 proteins revealed that these residues are also 
highly conserved (data not shown), revealing the 
location of the C11 catalytic dyad.  
Five of the D-helices surrounding the E-sheet 
of PmC11 (D1, D2, D4, D6 and D7) are found in 
similar positions to the five structurally 
conserved helices in caspases and other 
members of clan CD, apart from family C80 (2). 
Other than its more H[WHQGHG ȕ-sheet, PmC11 
differs most significantly from other clan CD 
members at its C-terminus, where the CTD 
FRQWDLQV D IXUWKHU VHYHQ Į-KHOLFHV DQG IRXU ȕ-
VWUDQGVDIWHUȕ 
 
Auto-Processing of PmC11—Purification of 
recombinant PmC11 (MW = 42.6 kDa) revealed 
partial processing into two cleavage products of 
26.4 and 16.2 kDa, related to the observed 
cleavage at K147 in the crystal structure (Fig. 
2A). Incubation of PmC11 at 37 °C for 16 h, 
resulted in a fully processed enzyme that 
remained as an intact monomer when applied to 
a size-exclusion column (Fig. 2B). The single 
cleavage site of PmC11 at K147 is found 
immediately after D3, in loop L5 within the 
central E-sheet (Figs. 1A, B and 2A). The two 
ends of the cleavage site are remarkably well 
ordered in the crystal structure and displaced 
from one another by 19.5 Å (Fig. 2A). 
Moreover, the C-terminal side of the cleavage 
site resides near to the catalytic dyad with A148 
being 4.5 and 5.7 Å from H133 and C179, 
respectively. Consequently, it appears feasible 
that the helix attached to K147 (D3) could be 
responsible for steric auto-inhibition of PmC11 
as K147 moves to form a covalent bond with 
A148. Prior to cleavage this would limit access 
to the active site; thus, the cleavage would be 
required for full activation of PmC11. To 
investigate this possibility, two mutant forms of 
the enzyme were created: PmC11C179A
 (a 
catalytically inactive mutant) and PmC11K147A (a 
cleavage-site mutant). Initial SDS-PAGE and 
western blot analysis of both mutants revealed 
no discernible processing occurred as compared 
to active PmC11 (Fig. 2C). The PmC11K147A 
mutant enzyme had a markedly different 
reaction rate (Vmax) compared to WT, where 
the reaction velocity of PmC11 was 10 times 
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greater than that of PmC11K147A (Fig. 2D). Taken 
together, these data reveal that PmC11 requires 
processing at K147 for optimum activity. 
 
To investigate whether processing is a result of 
intra or inter-molecular cleavage, the 
PmC11C179A mutant was incubated with 
increasing concentrations of processed and 
activated PmC11. These studies revealed that 
there was no apparent cleavage of PmC11C179A 
by the active enzyme at low concentrations of 
PmC11 and that only limited cleavage was 
observed when the ratio of active enzyme 
(PmC11: PmC11C179A) was increased to ~1:10 
and 1:4, with complete cleavage observed at a 
ratio of 1:1 (Fig. 2E). This suggests that the 
limited cleavage was most likely an effect of the 
increasing concentration of PmC11 and intra-
molecular cleavage.  Collectively, these data 
suggest that a pro-form of PmC11 is auto-
inhibited by a section of L5 blocking access to 
the active site, prior to intra-molecular cleavage 
at K147. This cleavage subsequently allows 
movement of the region containing K147 and the 
active site to open up for substrate access. 
 
Substrate specificity of PmC11—The 
autocatalytic cleavage of PmC11 at K147 
(sequence KLK^A) demonstrates that the 
enzyme accepts substrates with Lys in the P1 
position. The substrate specificity of the enzyme 
was further tested using a variety of fluorogenic 
substrates. As expected, PmC11 showed no 
activity against substrates with Pro or Asp in P1 
but was active towards substrates with a basic 
residue in P1 such as Benzoyl-L-Arg-4-
methylcoumaryl-7-amide (Bz-R-AMC), 
benzyloxycarbonyl-Gly-Gly-Arg-AMC (Z-
GGR-AMC) and t-Butyloxycarbonyl-Val-Leu-
Lys (BOC-VLK-AMC). The rate of cleavage 
was ~3-fold greater toward the single Arg 
substrate Bz-R-AMC than the other two (Fig. 
2F) and, unexpectedly, PmC11 showed no 
activity towards BOC-K-AMC. These results 
confirm that PmC11 accepts substrates 
containing Arg or Lys in P1 with a possible 
preference for Arg. 
 The catalytic dyad of PmC11 sits near the 
bottom of an open pocket on the surface of the 
enzyme at a conserved location in the clan CD 
family (2). The PmC11structure reveals that the 
catalytic dyad forms part of a large acidic pocket 
(Fig. 2G), consistent with a binding site for a 
basic substrate. This pocket is lined with the 
potential functional side chains of N50, D177 
and T204 with the side chains of G134, D207 
and M205 also contributing to the pocket (Fig. 
2A). Interestingly, these residues are in regions 
that are structurally similar to those involved in 
the S1 binding pockets of other clan CD 
members (shown in (2)).  
 
Since PmC11 recognises basic substrates, the 
tetra-peptide inhibitor Z-VRPR-FMK was tested 
as an enzyme inhibitor and was found to inhibit 
both the auto-processing and activity of PmC11 
(Fig. 3A). Z-VRPR-FMK was also shown to 
bind to the enzyme: a size-shift was observed, by 
SDS-PAGE analysis, in the larger processed 
product of PmC11 suggesting that the inhibitor 
bound to the active site (Fig. 3B). A structure 
overlay of PmC11 with the MALT1-
paracacaspase (MALT1-P), in complex with Z-
VRPR-FMK (35), revealed that the PmC11 dyad 
sits in a very similar position to that of active 
MALT1-P and that N50, D177 and D207 
superimpose well with the principal MALT1-P 
inhibitor binding residues (D365, D462 and 
E500, respectively (VRPR-FMK from MALT1-
P with the corresponding PmC11 residues from 
the structural overlay is shown in Fig. 1D), as 
described in (5)). D177 is located near the 
catalytic cysteine and is conserved throughout 
the C11 family, suggesting it is the primary S1 
binding site residue. In the structure of PmC11, 
D207 resides on a flexible loop pointing away 
from the S1 binding pocket (Fig. 1D). However, 
this loop has been shown to be important for 
substrate binding in clan CD (2) and this residue 
could easily rotate and be involved in substrate 
binding in PmC11. Thus, N50, D177 and D207 
are most likely responsible for the substrate 
specificity of PmC11. D177 is highly conserved 
throughout the clan CD C11 peptidases and is 
thought to be primarily responsible for the 
substrate specificity of the clan CD enzymes, as 
also illustrated from the proximity of these 
residues relative to the inhibitor Z-VRPR-FMK 
when PmC11 is overlayed on the MALT1-P 
structure (Fig. 3C). 
 
Comparison with clostripain—Clostripain is 
the founding member of the C11 peptidases and 
contains an additional 149 residues compared to 
PmC11. A multiple sequence alignment revealed 
that most of the secondary structural elements 
are conserved between the two enzymes, 
although they are only  ~23% identical (Fig 1A). 
Nevertheless, PmC11 may be a good model for 
the core structure of clostripain. 
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The primary structural alignment also shows 
that the catalytic dyad in PmC11 is structurally 
conserved in clostripain (36) (Fig. 1A). Unlike 
PmC11, clostripain has two cleavage sites (R181 
and R190), which results in the removal of a 
nonapeptide, and is required for full activation of 
the enzyme (37) (highlighted in Fig. 1A). 
Interestingly, R190 was found to align with 
K147 in PmC11. In addition, the predicted 
primary S1-binding residue in PmC11 D177 also 
overlays with the residue predicted to be the P1 
specificity determining residue in clostripain 
(38) (D229, Fig. 1A). 
 
As studies on clostripain revealed addition of 
Ca2+ ions are required for full activation, the 
Ca2+ dependency of PmC11 was examined. 
Surprisingly, Ca2+ did not enhance PmC11 
activity and, furthermore, other divalent cations, 
Mg2+, Mn2+, Co2+, Fe2+, Zn2+ and Cu2+, were 
necessary for PmC11 activity (Fig. 3D). In 
support of these findings, EGTA did not inhibit 
PmC11 suggesting that, unlike clostripain, 
PmC11 does not require Ca2+ or other divalent 
cations, for activity. 
 
DISCUSSION 
 
The crystal structure of PmC11 now provides, 
three-dimensional information for a member of 
the clostripain C11 family of cysteine 
peptidases. The enzyme exhibits all of the key 
structural elements of clan CD members, but is 
unusual in that it has a nine-stranded central E-
sheet with a novel C-terminal domain. The 
structural similarity of PmC11 with its nearest 
structural neighbours in the PDB is decidedly 
low, overlaying better with six-stranded caspase-
7 than any of the other larger members of the 
clan (Table 3). The substrate specificity of 
PmC11 is Arg/Lys and the crystal structure 
revealed an acidic pocket for specific binding of 
such basic substrates. In addition, the structure 
suggested a mechanism of self-inhibition in both 
PmC11 and clostripain and an activation 
mechanism that requires auto-processing. 
PmC11 differs from clostripain in that is does 
not appear to require divalent cations for 
activation. 
 
Several other members of clan CD require 
processing for full activation including legumain 
(39), gingipain-R (40), MARTX-CPD (8) and 
the effector caspases, e.g. caspase-7 (41). To 
date, the effector caspases are the only group of 
enzymes that require cleavage of a loop within 
the central E-sheet. This is also the case in 
PmC11, although the cleavage loop is 
structurally different to that found in the 
caspases, it follows the catalytic His (Fig. 1A), 
as opposed to the Cys as in the caspases. 
 
All other clan CD members requiring cleavage 
for full activation do so at sites external to their 
central sheets (2). The caspases and gingipain-R 
have both been shown to undergo inter-
molecular (trans) cleavage and legumain and 
MARTX-CPD are reported to perform intra-
molecular (cis) cleavage. In addition, several 
members of clan CD exhibit self-inhibition, 
whereby regions of the enzyme block access to 
the active site (2). Like PmC11, these structures 
show preformed catalytic machinery and for a 
substrate to gain access, movement and/or 
cleavage of the blocking region is required. 
 
The structure of PmC11 gives the first insight 
into this class of relatively unexplored family of 
proteins and should allow important catalytic 
and substrate binding residues to be identified in 
a variety of orthologues. Indeed, insights gained 
from an analysis of the PmC11 structure 
revealed the identity of the Trypanosoma brucei 
PNT1 protein as a C11 cysteine peptidase with 
an essential role in organelle replication (42). 
The PmC11 structure should provide a good 
basis for structural modelling and, given the 
importance of other clan CD enzymes, this work 
should also advance the exploration of these 
peptidases and potentially identify new 
biologically important substrates.  
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FIGURE LEGENDS 
FIGURE 1. Crystal structure of a C11 peptidase from Parabacteroides merdae. (A) Primary 
sequence alignment of PmC11 (Uniprot ID: A7A9N3) and clostripain (Uniprot ID: P09870) with 
identical residues highlighted in grey shading. The secondary structure of PmC11 from the crystal 
structure is mapped onto its sequence with the position of the PmC11 catalytic dyad, auto-catalytic 
cleavage site (K147), and S1 binding pocket Asp (D211) highlighted by a red star, a red 
downturned triangle, and a red upturned triangle, respectively. Connecting loops are colored gray, 
the main ȕ-sheet is in orange, with other strands in olive, Į- helices are in blue and the nonapeptide 
linker of clostripain that is excised upon auto-cleavage is underlined in red. Sequences around the 
catalytic site of clostripain and PmC11 align well. (B) Topology diagram of PmC11 colored as in B 
except that additional (non-core) ȕ-strands are in yellow. Helices found on either side of the central 
ȕ-sheet are shown above and below the sheet, respectively. The position of the catalytic dyad (H, 
C) and the processing site (K147) are highlighted. Helices (1–14) and E-strands (1–9 and A–F) are 
numbered from the N-terminus. The core caspase fold is highlighted in the grey box. (C) Tertiary 
structure of PmC11. The N and C termini (N, C) of PmC11 along with the central ȕ-sheet (1-9), 
helix Į5, and helices D8, D11 and D13 from the C-terminal domain, are all labelled. Loops are 
colored gray, the main ȕ-sheet is in orange, with other ȕ-strands in yellow, and Į-helices are in 
blue.  
 
FIGURE 2.  Biochemical and structural characterization of PmC11. (A) Ribbon representation of 
the overall structure of PmC11 illustrating the catalytic site, cleavage site displacement, and 
potential S1 binding site. The overall structure of PmC11 is shown in grey, looking down into the 
catalytic site with the catalytic dyad in red, The two ends of the autolytic cleavage site (K147 and 
A148, green) are displaced by 19.5 Å (thin black line) from one another and residues in the 
potential substrate binding pocket are highlighted in blue. (B) Size exclusion chromatography of 
PmC11. PmC11 migrates as a monomer with a molecular mass around 41 kDa calculated from 
protein standards of known molecular weights. Elution fractions across the major peak (1-6) were 
analyzed by SDS-PAGE on a 4-12 % gel in MES buffer. (C) The active form of PmC11 and two 
mutants PmC11C179A (C) and PmC11K147A (K) were examined by SDS-PAGE (lane 1) and Western 
Blot analysis using an anti-His antibody (lane 2) show that PmC11 auto-processes, whereas 
mutants, PmC11C179A and PmC11K147A, do not show auto-processing in vitro. (D) Cysteine 
peptidase activity of PmC11.  Km and Vmax of PmC11 and K147A mutant were determined by 
monitoring change in the fluorescence corresponding to AMC release from Bz-R-AMC. Reactions 
were performed in triplicate and representative values ± S.D. are shown. (E) Intramolecular 
processing of PmC11C179A by PmC11. PmC11C179A (20 µg) was incubated overnight at 37°C with 
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increasing amounts of processed PmC11 and analysed on a 10% SDS-PAGE gel. Inactive 
PmC11C179A was not processed to a major extent by active PmC11 until around a ratio of 1:4 (5 µg 
of active PmC11). A single lane of 20 µg of active PmC11 (labelled 20) is shown for comparison. 
(F) Activity of PmC11 against basic substrates. Specific activity is shown ± S.D. from three 
independent experiments. (G) Electrostatic surface potential of PmC11 shown in a similar 
orientation as Fig. S4, where blue and red denote positively and negatively charged surface 
potential, respectively, contoured at ±5 kT/e. The position of the catalytic dyad, one potential key 
substrate binding residue D177, and the ends of the cleavage site K147 and A148 are indicated. 
 
FIGURE 3. PmC11 binds and is inhibited by Z-VRPR-FMK and does not require Ca2+ for activity. 
(A) PmC11 activity is inhibited by Z-VRPR-FMK. Cleavage of Bz-R-AMC by PmC11 was 
measured in a fluorometric activity assay with (+, purple) and without (-, red) Z-VRPR-FMK. The 
relative fluorescence units of AMC released are plotted against time (min) (n=3; ±SD). (B) Gel-
shift assay reveals that Z-VRPR-FMK binds to PmC11. PmC11 was incubated with (+) or without 
(-) Z-VRPR-FMK and the samples analysed on a 10% SDS-PAGE gel. A size-shift can be 
observed in the larger processed product of PmC11 (26.1 kDa). (C) PmC11 with the Z-VRPR-
FMK from the MALT1-paracacaspase (MALT1-P) superimposed. A 3D structural overlay of Z-
VRPR-FMK from the MALT1-P complex onto PmC11. The position and orientation of Z-VRPR-
FMK was taken from superposition of the PmC11 and MALTI_P structures and indicates the 
presumed active site of PmC11. Residues surrounding the inhibitor are labelled and represent 
potentially important binding-site residues, labelled in black and shown in an atomic 
representation. Carbon atoms are shown in grey, nitrogen in blue, and oxygen in red. (C) Divalent 
cations do not increase the activity of PmC11. The cleavage of Bz-R-AMC by PmC11 was 
measured in the presence of the cations Ca2+, Mn2+, Zn2+, Co2+, Cu2+, Mg2+, Fe3+ with EGTA as a 
negative control, and relative fluorescence measured against time (min). The addition of cations 
produced no improvement in activity of PmC11 when compared in the presence of EGTA, 
suggesting that PmC11 does require metal ions for proteolytic activity. Furthermore, Cu2+, Fe2+, 
Zn2+ appear to inhibit PmC11. 
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TABLE 1. Crystallographic statistics for PDB ID 3UWS. 
   
Data collection
 
 
Wavelength (Å) 0.9793 
Spacegroup P21 
Unit cell dimensions a, b, c cȕq  39.11, 108.68, 77.97; ȕ 94.32q 
Resolution range (Å) 28.73–1.70 (1.79-1.70) 
Unique reflections                                    70,913 
Rmerge on I (%) 10.2 (49.0) 
Rmeas on I (%) 11.0 (52.7) 
Rpim on I (%) 4.1 (19.2) 
I/ ı I 15.6 (4.6)  
Wilson B (Å2) 15.9 
Completeness (%) 99.6 (99.8)  
Multiplicity 7.3 (7.5) 
 
Model and Refinement
 
 
Reflections (total/test) 70,883/3,577 
Rcryst/Rfree (%) 14.3/17.5 
  No. protein residues/atoms 700/5612
 
 No. water/EDO molecules  690/7 
 ESU based on Rfree (Å)  0.095 
 B-values (Å2)
 
Average isotropic B (overall) 20.0 
Protein overall 18.8 
All main/side chains 16.7/20.8 
Solvent/EDO 29.4/35.6 
R.M.S deviations 
Bond lengths (Å ) 0.01 
       Bond angles (°) 1.6
 
Ramachandran analysis (%) 
Favoured regions 97.0 
       Allowed regions 3.0 
       Outliers 0.0 
 
Values in parentheses are for the highest resolution shell. Rmerge= ȈhklȈi|Ii(hkl) - <I(hkl)>|/Ȉhkl 
Ȉi(hkl); Rmeas = Ȉhkl[N/(N-1)]1/2Ȉi|Ii(hkl) - <I(hkl)>|/ȈhklȈiIi(hkl); and and Rpim. (precision-
indicating Rmerge   Ȉhkl[(1/(N-1)]½ Ȉi|Ii (hkl) - <I(hkl!_  ȈhklȈi Ii(hkl) (43),  where N is the 
multiplicity of reflection hkl, and Ii(hkl) and <I(hkl)> are the intensity of the ith measurement and 
the average intensity of reflection hkl, respectively (44).  Rcryst and Rfree=  ¦~_Fobs_-_Fcalc_~¦_Fobs_  
for reflections in the working and test sets respectively, where Fobs  and Fcalc  are the observed 
and calculated structure-factor amplitudes, respectively. Rfree is the same as Rcryst but for 5% of 
the total reflections chosen at random and omitted from structural refinement. ESU is the estimated 
standard uncertainties of atoms and the average isotropic B includes TLS and residual B 
components. 
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TABLE 2. Summary of PDBeFOLD (45) superposition of structures found to be most similar to 
PmC11 in the PBD based on DaliLite (46). The results are ordered in terms of structural homology 
(QH), where %SSEPC-X is the percentage of the SSEs in the PmC11 that can be identified in the 
target X (where X=Caspase-7 (47), Legumain (3) Gingipain (48), and TcdB-CPD (49) %SSEX-PC is 
the percentage of SSEs in X (as above) that can be identified in PmC11 (as above); % Seq. ID is 
the percentage sequence identity after structural alignment; Nalign is the number of matched 
residues and RMSD is the root mean squared deviation on the CD positions of the matched 
residues. 
Figure 1
Figure 2
Figure 3
